Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | STAMBP | O95630 | 1/20 | 0.54 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804653 | 0.87 | NPC1 (0.70) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL23985881 | 0.83 | MAPT (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11761142 | 0.82 | NPC1 (0.82) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL9416606 | 0.82 | NPC1 (0.82) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL16562244 | 0.81 | RAB9A (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26358232 | 0.81 | NPC1 (0.63) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3098294 | 0.81 | MEN1 (0.77) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL8975296 | 0.81 | BCHE (0.72) | NPC1ALDH1A1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1767586 | 0.80 | BCHE (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5215056 | 0.80 | KDM1A (0.72) | NPC1RAB9AALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4143196-A1 | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | NPC1 1011/4885RAB9A 872/4885ALDH1A1 2405/4885 |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | NPC1 1197/4885RAB9A 600/4885ALDH1A1 3446/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | NPC1 909/4885RAB9A 1388/4885ALDH1A1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.